The neurodegenerative disorder drug developer has emerged from stealth to commercialise Howard Hughes Medical Institute research.
Faze Medicines, a US-based molecular therapeutics developer co-founded by researchers at Howard Hughes Medical Institute, has officially launched with $81m in series A funding led by venture capital firm Third Rock Ventures.
Pharmaceutical firms Novartis, Eli Lilly and AbbVie also provided capital, as did Alexandria Venture Investments, the VC arm of real estate investment trust Alexandria Real Estate Equities, Catalio Capital Management and Casdin Capital.
Novartis and AbbVie participated in the round through corporate venturing vehicles Novartis Venture…
